Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 19 Breast Neoplasms 18 Fallopian Tube Neoplasms 13 Neoplasm Metastasis 10 Triple Negative Breast Neoplasms 8 Prostatic Neoplasms 8 Neoplasms 7 Endometrial Neoplasms 7 Small Cell Lung Carcinoma 5 Pancreatic Neoplasms 5 Parkinson Disease 4, Autosomal Dominant Lewy Body 4 Metastatic Castration-resistant Prostate Cancer 4 Carcinoma, Non-Small-Cell Lung 4 Stomach Neoplasms 3 Solid Tumors 3 Neuroendocrine Tumors 3 Lymphoma, Non-Hodgkin 3 Lung Neoplasms 3 Glioma 3 Urinary Bladder Neoplasms 2 Sarcoma 2 Recurrence 2 Pheochromocytoma 2 Paraganglioma 2 Osteosarcoma 2 Neuroblastoma 2 Multiple Myeloma 2 Medulloblastoma 2 Glioblastoma 2 Ependymoma 2

Interventions

Cisplatin 18 Gemcitabine 14 Radiotherapy, Intensity-Modulated 11 Magnetic Resonance Spectroscopy 8 toripalimab 7 Specimen Handling 7 Capecitabine 7 Platinum 5 Drug Therapy 5 1,2-diaminocyclohexaneplatinum II citrate 5 camrelizumab 4 Radiotherapy 4 Nivolumab 4 spartalizumab 3 sintilimab 3 anlotinib 3 Immunoglobulin G 3 Immune Checkpoint Inhibitors 3 Docetaxel 3 Disulfides 3 atezolizumab 2 Radiation 2 Phantoms, Imaging 2 Ipilimumab 2 Carboplatin 2 CTLA-4 Antigen 2 Biopsy 2 Bevacizumab 2 18-O-demethylcervinomycin A2 2 tislelizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Nasopharyngeal Carcinoma × olaparib × 90 days × Clear all

NCT04825990 2026-06-01

POINT

Gruppo Oncologico del Nord-Ovest

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡